Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Revenue
65,768
16,286
16,400
17,276
15,806
15,529
Revenue Growth (YoY)
3%
5%
5%
4%
-2%
-2%
Cost of Revenue
14,423
2,944
4,239
3,783
3,457
3,383
Gross Profit
51,345
13,342
12,161
13,493
12,349
12,146
Selling, General & Admin
10,844
2,668
2,895
2,633
2,648
2,552
Research & Development
23,801
12,558
3,247
4,001
3,995
3,621
Operating Expenses
34,645
15,226
6,142
6,634
6,643
6,173
Other Non Operating Income (Expenses)
741
164
204
152
221
239
Pretax Income
11,630
-3,534
3,420
6,745
4,999
5,903
Income Tax Expense
2,696
709
458
958
571
818
Net Income
8,935
-4,240
2,963
5,785
4,427
5,079
Net Income Growth
-49%
-183%
-21%
83%
-19%
7%
Shares Outstanding (Diluted)
2,472
2,472
2,486
2,498
2,513
2,531
Shares Change (YoY)
-2%
-2%
-2%
-2%
-1%
-1%
EPS (Diluted)
3.61
-1.72
1.19
2.32
1.76
2.01
EPS Growth
-47%
-186%
-20%
87%
-18%
7%
Free Cash Flow
--
--
1,824
6,835
2,529
1,172
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
78.06%
81.92%
74.15%
78.1%
78.12%
78.21%
Operating Margin
25.39%
-11.56%
36.7%
39.7%
36.1%
38.46%
Profit Margin
13.58%
-26.03%
18.06%
33.48%
28%
32.7%
Free Cash Flow Margin
--
--
11.12%
39.56%
16%
7.54%
EBITDA
--
--
8,485
8,013
6,825
7,072
EBITDA Margin
--
--
51.73%
46.38%
43.17%
45.54%
D&A For EBITDA
--
--
2,466
1,154
1,119
1,099
EBIT
16,700
-1,884
6,019
6,859
5,706
5,973
EBIT Margin
25.39%
-11.56%
36.7%
39.7%
36.1%
38.46%
Effective Tax Rate
23.18%
-20.06%
13.39%
14.2%
11.42%
13.85%
Follow-Up Questions
What are Merck & Co Inc's key financial statements?
According to the latest financial statement (Form-10K), Merck & Co Inc has a total asset of $0, Net loss of $0
What are the key financial ratios for MRK?
Merck & Co Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Merck & Co Inc's revenue broken down by segment or geography?
Merck & Co Inc largest revenue segment is Pharmaceutical, at a revenue of 58,142,000,000 in the most earnings release.For geography, United States is the primary market for Merck & Co Inc, at a revenue of 36,510,000,000.
Is Merck & Co Inc profitable?
no, according to the latest financial statements, Merck & Co Inc has a net loss of $0
Does Merck & Co Inc have any liabilities?
no, Merck & Co Inc has liability of 0
How many outstanding shares for Merck & Co Inc?
Merck & Co Inc has a total outstanding shares of 0